Parabilis, fresh from inking Regeneron pact, plans IPO to fund tumor drug’s phase 3 push

With the ink barely dry on an antibody-drug conjugate-style deal with Regeneron, Parabilis Medicines has now turned its attention to the public markets. With the ink barely dry on an antibody-drug conjugate-style deal with Regeneron, Parabilis Medicines has now turned its attention to the public markets. Biotech Cell & Gene Therapy Clinical Data Venture Capital Deals Research Medtech Devices Diagnostics AI and Machine Learning CRO Special Reports Trending Biologics Clinical Development Ophthalmology Cell & Gene Therapy Drug Development Small Molecule Research & Development Fierce 50 Special Report Awards Gala Awards Outsourcing Awards Innovation Awards Resources Fierce Events Industry Events…

Source: FierceBiotech